Sinovac Biotech Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 73   

Articles published

SVA 5.24 +0.01 (0.19%)
price chart
Sinovac Biotech, Ltd. (NASDAQ:SVA) Short Interest Update
Sinovac Biotech, Ltd. (NASDAQ:SVA) has shown a rise of 0.2% or 1,914 shares in the short positions. The bets have increased to 1,030,582 shares on July 15,2015 from 1,028,668 shares on June 30,2015.
Sinovac Biotech Ltd. (SVA) F4Q14 Earnings Call Transcript (SVA)
Greetings and welcome to the Sinovac Biotech Limited Fourth Quarter and 2014 Full Year Earnings Conference Call. At this time all participants are in a listen-only mode.
Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results  PR Newswire (press release)
Short Interest Update of Sinovac Biotech, Ltd. (NASDAQ:SVA)
Sinovac Biotech, Ltd. (NASDAQ:SVA) stated loss of 534,128 shares or 34.2% in the short interest. The short interest registered from 1,562,796 on June 15,2015 to 1,028,668 on June 30,2015.
Sinovac Biotech Critics May Soon Have To Put Their 'Foot Where Their Mouth Is ...
Sinovac Biotech is an China-based biotechnology company focused on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis A and B, seasonal influenza, ...
Sinovac Receives Site Inspection Notification for EV71 Vaccine Production ...  PR Newswire (press release)
Sinovac Biotech, Ltd. (NASDAQ:SVA) Analyst Rating Update
Analysts at Zacks have given a short term rating of hold on Sinovac Biotech (NASDAQ:SVA) with a rank of 3. The company has received an average rating of 1 from 1 brokerage firms.
Today's Stocks: Sinovac Biotech Ltd. (NASDAQ:SVA), Xerox Corporation (NYSE:XRX ...
Sinovac Biotech Ltd. (NASDAQ:SVA), announced that it will hold its 2015 Annual Meeting of Shareholders on Tuesday, August 11, 2015 at 9:00 a.m.
Sinovac Biotech, Ltd. Short Interest Update
Sinovac Biotech, Ltd. (NASDAQ:SVA) ensharesed a rise of 5.9% or 86,963 shares in the short positions. The number escalated from 1,475,833 on May 29,2015 to 1,562,796 on June 15,2015.
Overpriced for Now: Sinovac Biotech (NASDAQ:SVA)
We look at Sinovac Biotech Ltd. (NASDAQ:SVA) a company in the Healthcare industry getting a lot of share market attention at present, to assess if it provides value for investors considering buying or selling it.
Company Shares of Sinovac Biotech, Ltd. Drops by -9.45%
Sinovac Biotech, Ltd. (NASDAQ:SVA) has lost 9.45% during the past week and dropped 8.14% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 9.08%.
Exclusive: Sinovac IR Director Explains Massive Revenue Opportunity
In an exclusive interview with Benzinga, director of Investor Relations, Helen Yang, discussed Sinovac's (NASDAQ: SVA) future opportunities.
Related articles »